RAMM Pharma
A leader in the research and development of cannabinoid pharmaceutical formulations..
Launch date
Employees
Market cap
€1.6m
Enterprise valuation
(€40k) (Public information from Sep 2024)
Share price
CAD0.02 RAMM.CN
Toronto Ontario (HQ)
Financials
Estimates*
CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 8.3m | 5.6m | 5.4m | 4.1m | 3.9m | 5.1m |
% growth | - | (33 %) | (3 %) | (24 %) | (5 %) | 30 % |
EBITDA | (<1m) | (2.1m) | (6.8m) | (6.3m) | (6.6m) | (5.2m) |
% EBITDA margin | (3 %) | (37 %) | (125 %) | (154 %) | (169 %) | (103 %) |
Profit | (<1m) | (6.8m) | (7.4m) | (7.1m) | (21.0m) | (7.7m) |
% profit margin | (8 %) | (122 %) | (136 %) | (173 %) | (538 %) | (152 %) |
EV / revenue | - | - | 5.0x | 9.8x | 4.0x | 0.3x |
EV / EBITDA | - | - | -4.0x | -6.4x | -2.3x | -0.2x |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | CAD35.3m | Late VC |
N/A | N/A | IPO | |
* | N/A | $1.0m | Post IPO Equity |
* | N/A | CAD1.0m | Private Placement non VC |
Total Funding | €23.5m |